Avedro, ACOS commence accelerated corneal cross-linking Phase 3 study

ACOS (The American-European Congress of Ophthalmic Surgery) and Avedro, Inc. jointly announced today the initiation of a Phase 3, multi-center, randomized, controlled evaluation to study accelerated corneal collagen cross-linking in eyes with keratoconus or corneal ectasia after refractive surgery. ACOS is sponsoring the study, which will be conducted in 100 clinical centers across the United States. Each of the 100 clinical sites will use Avedro's KXL™ System and VibeX™ (riboflavin ophthalmic solution) to treat all patients enrolled in the study.    

Stephen G. Slade, MD, President of ACOS said, "In the absence of any FDA approval for corneal cross-linking, ACOS is delighted to partner with Avedro on this clinical study which allows keratoconic and ectasia patients across the United States to receive treatment from leading ophthalmic surgeons using a uniform treatment protocol and the most highly-developed technology available today."

"Avedro is proud to be associated with ACOS and very pleased our KXL System and VibeX riboflavin will now be available to patients in 100 clinics throughout the United States as part of this study," said David Muller, PhD, President and CEO of Avedro. "We now look forward to working with some of America's top ophthalmologists engaged in the important clinical work of improving the sight and quality of life of thousands of keratoconus and ectasia patients."